Cytosorbents (CTSO) Competitors $1.00 +0.02 (+1.52%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$1.00 0.00 (0.00%) As of 01/31/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CTSO vs. AVR, OBIO, PROF, SKIN, BWAY, KRMD, NVRO, INFU, LAKE, and TLSIShould you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Anteris Technologies Global (AVR), Orchestra BioMed (OBIO), Profound Medical (PROF), Beauty Health (SKIN), BrainsWay (BWAY), KORU Medical Systems (KRMD), Nevro (NVRO), InfuSystem (INFU), Lakeland Industries (LAKE), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical equipment" industry. Cytosorbents vs. Anteris Technologies Global Orchestra BioMed Profound Medical Beauty Health BrainsWay KORU Medical Systems Nevro InfuSystem Lakeland Industries TriSalus Life Sciences Cytosorbents (NASDAQ:CTSO) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, community ranking, risk, valuation, dividends, earnings and analyst recommendations. Do analysts rate CTSO or AVR? Cytosorbents currently has a consensus target price of $4.67, indicating a potential upside of 364.34%. Anteris Technologies Global has a consensus target price of $16.50, indicating a potential upside of 166.13%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than Anteris Technologies Global.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytosorbents 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00Anteris Technologies Global 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CTSO or AVR more profitable? Anteris Technologies Global has a net margin of 0.00% compared to Cytosorbents' net margin of -49.47%. Anteris Technologies Global's return on equity of 0.00% beat Cytosorbents' return on equity.Company Net Margins Return on Equity Return on Assets Cytosorbents-49.47% -118.54% -42.31% Anteris Technologies Global N/A N/A N/A Does the MarketBeat Community believe in CTSO or AVR? Cytosorbents received 435 more outperform votes than Anteris Technologies Global when rated by MarketBeat users. However, 100.00% of users gave Anteris Technologies Global an outperform vote while only 74.79% of users gave Cytosorbents an outperform vote. CompanyUnderperformOutperformCytosorbentsOutperform Votes43974.79% Underperform Votes14825.21% Anteris Technologies GlobalOutperform Votes4100.00% Underperform VotesNo Votes Do insiders & institutionals believe in CTSO or AVR? 32.9% of Cytosorbents shares are owned by institutional investors. 6.6% of Cytosorbents shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, CTSO or AVR? Anteris Technologies Global has lower revenue, but higher earnings than Cytosorbents. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytosorbents$36.35M1.51-$28.51M-$0.36-2.79Anteris Technologies GlobalN/AN/AN/AN/AN/A Does the media favor CTSO or AVR? In the previous week, Cytosorbents had 3 more articles in the media than Anteris Technologies Global. MarketBeat recorded 4 mentions for Cytosorbents and 1 mentions for Anteris Technologies Global. Anteris Technologies Global's average media sentiment score of 1.14 beat Cytosorbents' score of 0.37 indicating that Anteris Technologies Global is being referred to more favorably in the news media. Company Overall Sentiment Cytosorbents Neutral Anteris Technologies Global Positive SummaryCytosorbents beats Anteris Technologies Global on 7 of the 13 factors compared between the two stocks. Get Cytosorbents News Delivered to You Automatically Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTSO vs. The Competition Export to ExcelMetricCytosorbentsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$54.95M$4.88B$5.57B$9.20BDividend YieldN/A51.39%5.31%3.99%P/E Ratio-2.7915.2564.1014.76Price / Sales1.5157.261,272.7791.55Price / CashN/A52.1145.9637.70Price / Book1.938.145.124.71Net Income-$28.51M$89.07M$111.17M$224.24M7 Day Performance-3.37%-2.28%2.38%-0.17%1 Month Performance10.44%8.36%3.20%0.60%1 Year Performance-0.50%29.54%24.70%20.43% Cytosorbents Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTSOCytosorbents2.3504 of 5 stars$1.01+1.5%$4.67+364.3%-0.5%$54.95M$33.79M-2.79220Analyst ForecastShort Interest ↑AVRAnteris Technologies GlobalN/A$6.00+0.2%$16.50+175.0%N/A$215.64MN/A0.00138Positive NewsOBIOOrchestra BioMed2.8344 of 5 stars$5.59+4.9%$16.25+190.7%-26.0%$212.48M$2.76M-3.474PROFProfound Medical2.2505 of 5 stars$6.94-1.6%$14.25+105.3%-27.7%$208.48M$7.20M-5.18150News CoverageSKINBeauty Health2.0717 of 5 stars$1.65-4.6%$2.55+54.5%-43.0%$204.80M$347.62M-3.931,030Gap DownBWAYBrainsWay3.9264 of 5 stars$10.47-2.1%$13.17+25.8%+67.9%$196.94M$31.78M104.71120Short Interest ↓KRMDKORU Medical Systems1.4549 of 5 stars$4.15+0.7%$4.50+8.4%+111.1%$190.24M$28.52M-16.6080Short Interest ↓News CoveragePositive NewsNVRONevro1.3411 of 5 stars$5.00-3.1%$6.30+26.0%-69.2%$187.35M$425.17M-2.651,215Gap UpINFUInfuSystemN/A$8.27+1.8%$13.00+57.2%-12.4%$175.82M$125.79M137.86410LAKELakeland Industries4.8301 of 5 stars$23.10+1.6%$27.50+19.0%+28.8%$171.17M$124.69M-256.671,750Short Interest ↑TLSITriSalus Life Sciences3.8542 of 5 stars$5.30+2.3%$11.79+122.4%-43.5%$161.60M$18.51M-2.13106Insider TradeNews CoveragePositive NewsHigh Trading Volume Related Companies and Tools Related Companies AVR Competitors OBIO Competitors PROF Competitors SKIN Competitors BWAY Competitors KRMD Competitors NVRO Competitors INFU Competitors LAKE Competitors TLSI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTSO) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump loves DeepSeekPresident Trump could be ecstatic. And it's all thanks to DeepSeek. The secretive Chinese startup just r...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredNew catalyst on Wall Street’s radar for this week (NOT Trump)Wall Street is already looking past Trump… To a new catalyst on the near horizon that could be even bigger ...Timothy Sykes | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTSO Stock Alerts